Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study

#4574

Introduction: Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.

Aim(s): To describe patients’ injection experiences and satisfaction with, and preferences for, the LAN-PF and LAN-RA syringes for the treatment of GEP-NETs or acromegaly.

Materials and methods: BackSOM (NCT06253897) is an ongoing, cross-sectional, non-interventional qualitative interview study of patients with GEP-NETs or acromegaly in France, Spain and the UK. Eligible patients must have received ≥2 injections with the LAN-PF syringe before transitioning to the LAN-RA syringe. They must have received ≥2 LAN-RA injections, with the last dose within the previous 12 months. One-to-one, semi-structured, qualitative patient telephone/video interviews have been conducted. The primary endpoint is the description of patients’ injection experiences and satisfaction with the LAN-PF and LAN-RA syringes. Secondary endpoints include the description of patients’ understanding of the reasons for switching syringe types, their perceptions of and preference for each syringe type, and experiences that are unique to patients who self-administer injections and to patients with each indication. A pilot study included one patient with GEP-NETs and one with acromegaly.

Conference:

Presenting Author: Hernando Cubero J

Authors: Rodien-Louw C, Simo-Servat A, Dubois M, Sheppard J, McDonnell M,

Keywords: gastroenteropancreatic neuroendocrine tumour, GEP-NET, acromegaly, lanreotide, LA-SSA, somatostatin, patient preference,